.jpg)
Use of TRF1 inhibitors for the treatment or prevention of brain cancer
WO2020/052772
The CNIO has developed TRF1 inhibitors and compositions comprising them for the prevention and/or treatment of brain cancer, for example, glioblastoma. The inventors have found TRF1 inhibitors and compositions comprising them for the treatment or prevention of brain cancer, such as glioblastoma, and particularly glioblastoma multiforme (GBM). PI3K inhibitors can be among the TRF1 inhibitors used. The invention also relates to a method for identifying compounds candidates to be used for treating glioblastoma or other cancers.
The inventors have found a therapy to target brain cancer, such as GBM, based on TRF1 inhibition. Compositions of the invention can comprise more than one TRF1 inhibitor, being particularly advantageous that at least one of the inhibitors is a PI3K inhibitor and that at least a second possible TRF1 inhibitor present selected, for example, from an RTK inhibitor, a MEK inhibitor, an ERK inhibitor, an HSP90 inhibitor, docetaxel or gemcitabine.